ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 661,46
1,21%
Dow Jones
38 921,73
0,22%
DAX
18 201,73
0,74%
Brent Oil
85,19
0,58%
Bitcoin
64 844,72
-0,18%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) Actualités

KALV KalVista Pharmaceuticals Inc

11,17
-0,20 (-1,76%)
Dernière mise à jour : 15:55:06
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
KalVista Pharmaceuticals Inc KALV NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,20 -1,76% 11,17 15:55:06
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
11,33 11,08 11,33 11,37
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/6/202412:30BWKalVista Submits New Drug Application to FDA for..
11/6/202400:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202412:30BWKalVista Pharmaceuticals Presents Data at Eastern Allergy..
04/6/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
03/6/202412:30BWKalVista Pharmaceuticals Presents Data on Persisting Unmet..
31/5/202422:09BWKalVista Pharmaceuticals Announces New England Journal of..
31/5/202418:15BWKalVista Pharmaceuticals Announces New England Journal of..
24/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202412:30BWKalVista Pharmaceuticals Announces Ten Abstracts Accepted..
21/5/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202412:30BWKalVista Pharmaceuticals to Present at Upcoming Investor..
02/5/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
01/5/202412:30BWKalVista Pharmaceuticals Highlights Strategic Plans for..
22/4/202412:30BWKalVista Pharmaceuticals Appoints William C. Fairey to Board..
03/4/202412:30BWKalVista Pharmaceuticals to Present at 23rd Annual Needham..
02/4/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
18/3/202411:30BWKalVista Pharmaceuticals Presents Real-World Data on Burden..
12/3/202411:30BWKalVista Pharmaceuticals Awarded UK Promising Innovative..
11/3/202421:37EDGAR2Form 8-K - Current report
11/3/202421:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/3/202411:30BWKalVista Pharmaceuticals Reports Third Fiscal Quarter..
08/3/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202412:30BWKalVista Pharmaceuticals to Present HAE Attack Journey Data..
07/3/202412:38EDGAR2Form 8-K - Current report
07/3/202412:30BWKalVista Pharmaceuticals Announces Appointment of Benjamin..
06/3/202412:30BWKalVista Pharmaceuticals to Participate in the Leerink..
04/3/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
27/2/202412:30BWKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE..
26/2/202412:30BWKalVista Pharmaceuticals Presents Additional Phase 3..
22/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202419:22EDGAR2Form SC 13D/A - General statement of acquisition of..
22/2/202403:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:49EDGAR2Form SC 13D/A - General statement of acquisition of..
20/2/202412:30BWKalVista Pharmaceuticals Awarded UK Innovation Passport for..
16/2/202422:32EDGAR2Form 8-K - Current report
16/2/202422:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202412:30BWKalVista Pharmaceuticals to Present Phase 3 Sebetralstat..
15/2/202412:30BWKalVista Pharmaceuticals Announces Pricing of a $160.1..

Dernières Valeurs Consultées

NASDAQ
KALV
KalVista Pharmaceuticals
BIT
Q00593
Leonteq Securities
NASDAQ
AVT
Avnet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés